|
1.
|
DN LouisH OhgakiOD WiestlerWK CaveneeThe
2007 WHO classification of tumours of the central nervous
systemActa
Neuropathol11497109200710.1007/s00401-007-0243-417618441
|
|
2.
|
JG GurneyN Kadan-LottickBrain and other
central nervous system tumors: rates, trends, and epidemiologyCurr
Opin Oncol13160166201010.1097/00001622-200105000-0000511307058
|
|
3.
|
SS BremPJ BiermanH BremCentral nervous
system cancersJ Natl Compr Canc Netw93524002011
|
|
4.
|
F Laigle-DonadeyJY DelattreGlioblastoma in
the elderlyGeriatr Psychol Neuropsychiatr Vieil91011062011(In
French)
|
|
5.
|
I BaldiA HuchetL BauchetH
LoiseauEpidemiology of
glioblastomaNeurochirurgie56433440201010.1016/j.neuchi.2010.07.01120869733
|
|
6.
|
L BauchetH Mathieu-DaudéP
Fabbro-PeraySociété Française de Neurochirurgie (SFNC)Club de
Neuro-Oncologie of the Société Française de Neurochirurgie
(CNO-SFNC)Société Française de Neuropathologie (SFNP)Association
des Neuro-Oncologues d'Expression Française (ANOCEF)Oncological
patterns of care and outcome for 952 patients with newly diagnosed
glioblastoma in 2004Neuro
Oncol12725735201010.1093/neuonc/noq03020364023
|
|
7.
|
S DeorahCF LynchZA SibenallerTC
RykenTrends in brain cancer incidence and survival in the United
States: surveillance, epidemiology, and end results program, 1973
to 2001Neurosurg Focus20E1201010.3171/foc.2006.20.4.E116709014
|
|
8.
|
HUCA tumour register. 2008 Annual Report.
Hospital Universitario Central de Asturias and Instituto
Universitario Oncológico, Principality of Asturias, 2008. ISSN
1138–8501. http://10.15.65.11/huca/web/contenidos/servicios/rt/rt2008/rt2008.pdf.
Accesed January 21, 2012
|
|
9.
|
R StuppWP MasonMJ van den BentEuropean
Organisation for Research and Treatment of Cancer Brain Tumor and
Radiotherapy GroupsNational Cancer Institute of Canada Clinical
Trials Group: Radiotherapy plus concomitant and adjuvant
temozolamide for glioblastomaN Engl J
Med352987996200510.1056/NEJMoa04333015758009
|
|
10.
|
R StuppME HegiWP MasonEuropean
Organisation for Research and Treatment of Cancer Brain Tumour and
Radiation Oncology GroupsNational Cancer Institute of Canada
Clinical Trials Group: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trialLancet Oncol104594662009
|
|
11.
|
M LacroixD Abi-SaidDR FourneyA
multivariate analysis of 416 patients with glioblastoma multiforme:
prognosis, extent of resection, and survivalJ
Neurosurg95190198200110.3171/jns.2001.95.2.019011780887
|
|
12.
|
JF MineoA BordronM BaronciniPrognosis
factors of survival time in patients with glioblastoma multiforme:
a multivariate analysis of 340 patientsActa Neurochir
(Wien)149245253200710.1007/s00701-006-1092-y17273889
|
|
13.
|
AA BrandesA TosoniE FranceschiM ReniG
GattaC VechtGlioblastoma in adultsCrit Rev Oncol
Hematol67139152200810.1016/j.critrevonc.2008.02.005
|
|
14.
|
M MaxwellSP NaberHJ WolfeET Hedley-WhyteT
GalanopoulosJ Neville-GoldenHN AntoniadesExpression of angiogenic
growth factor genes in primary human astrocytomas may contribute to
their growth and progressionCancer Res511345135119911705174
|
|
15.
|
JA TakahasiM FukumotoK IgarashiY OdaH
KikuchiM HatanakaCorrelation of Basic fibroblast growth factor
expression levels with the degree of malignancy and vascularity in
human gliomasJ
Neurosurg76792798199210.3171/jns.1992.76.5.07921564542
|
|
16.
|
J FolkmanTumor angiogenesis: Therapeutic
implicationsN Engl J
Med28511821186197110.1056/NEJM1971111828521084938153
|
|
17.
|
HS FriedmanMD PradosPY WenBevacizumab
alone and in combination with irinotecan in recurrent glioblastomaJ
Clin Oncol2747334740200910.1200/JCO.2008.19.872119720927
|
|
18.
|
AD NordenGS YoungK SetayeshBevacizumab for
recurrent malignant gliomas, efficacy, toxicity and patterns of
recurrenceNeurology70779787200810.1212/01.wnl.0000304121.57857.3818316689
|
|
19.
|
TN KreislL KimK MoorePhase II trial of
single-agent bevacizumab followed by bevacizumab plus irinotecan at
tumor progression in recurrent glioblastomaJ Clin
Oncol27740745200910.1200/JCO.2008.16.305519114704
|
|
20.
|
JJ VredenburghA DesjardinsJE
HerndonBevacizumab plus irinotecan in recurrent glioblastoma
multiformeJ Clin
Oncol2547224729200710.1200/JCO.2007.12.244017947719
|
|
21.
|
RM ZunigaR TorcuatorR JainEfficacy, safety
and patterns of response and recurrence in patients with recurrent
high-grade gliomas treated with bevacizumab plus irinotecanJ
Neurooncol91329336200910.1007/s11060-008-9718-y18953493
|
|
22.
|
V Stark-VanceBevacizumab and CPT-11 in the
treatment of relapsed malignant gliomaNeuro Oncol7Suppl369abstr
3422005
|
|
23.
|
S RavalS HwangL DorsettBevacizumab and
irinotecan in patients with recurrent glioblastoma multiformeJ Clin
Oncol25Supplabstr 20782007
|
|
24.
|
JJ VredenburghA DesjardinsJE Herndon
IIPhase II trial of bevacizumab and irinotecan in recurrent
malignant gliomaClin Cancer
Res1312531259200710.1158/1078-0432.CCR-06-230917317837
|
|
25.
|
SA AliWM McHaylehA AhmadBevacizumab and
irinotecan therapy in glioblastoma multiforme: a series of 13
casesJ
Neurosurg109268272200810.3171/JNS/2008/109/8/026818671639
|
|
26.
|
F BoksteinS ShpigelDT BlumenthalTreatment
with bevacizumab and irinotecan for recurrent high-grade glial
tumorsCancer11222672273200810.1002/cncr.2340118327820
|
|
27.
|
TF CloughesyMD PradosPY WenA phase II,
randomized, non-comparative clinical trial of the effect of
bevacizumab (BV) alone or in combination with irinotecan (CPT) on
6-month progression free survival (PFS6) in recurrent, treatment
refractory glioblastoma (GBM)J Clin Oncol26Supplabstr 2010b2008
|
|
28.
|
A DesjardinsDA ReardonJE Herndon
IIBevacizumab plus irinotecan in recurrent WHO grade 3 malignant
gliomasClin Cancer
Res1470687073200810.1158/1078-0432.CCR-08-026018981004
|
|
29.
|
S GuiuS TaillibertO
ChinotBevacizumab/irinotecan. An active treatment for recurrent
high grade gliomas: preliminary results of an ANOCEF Multicenter
StudyRev Neurol (Paris)1645885942008(In French)
|
|
30.
|
MR GilbertM WangK AldapeRTOG 0625: A phase
II study of bevacizumab with irinotecan in recurrent glioblastoma
(GBM)J Clin Oncol27Supplabstr 20112009
|
|
31.
|
PL NghiemphuW LiuY LeeBevacizumab and
chemotherapy for recurrent glioblastoma: a single-institution
experienceNeurology7212171222200910.1212/01.wnl.0000345668.03039.9019349600
|
|
32.
|
HS PoulsenK GrunnetM SorensenBevacizumab
plus irinotecan in the treatment patients with progressive
recurrent malignant brain tumoursActa
Oncol485258200910.1080/0284186080253792419031176
|
|
33.
|
T CloughesyJJ VredenburghB DayUpdated
safety and survival of patients with relapsed glioblastoma treated
with bevacizumab in the BRAIN studyJ Clin Oncol28Supplabstr
20082010
|
|
34.
|
A DesjardinsJJ VredenburghDA
ReardonLongterm survival from the initial trial of bevacizumab and
irinotecanJ Clin Oncol28Supplabstr 20452010
|
|
35.
|
MH CohenYL ShenP KeeganR PazdurFDA drug
approval summary: bevacizumab (Avastin) as treatment of recurrent
glioblastoma
multiformeOncologist1411311138200910.1634/theoncologist.2009-012119897538
|
|
36.
|
M SeizU KraVtCF FreyschlagLong-term
adjuvant administration of temozolomide in patients with
glioblastoma multiforme: experience of a single institutionJ Cancer
Res Clin Oncol13616911695201010.1007/s00432-010-0827-620177703
|
